AstraZeneca’s plan to produce its Covid-19 vaccine in Thailand has made significant progress and the first batch of vaccines will be ready for delivery to the government by June.
The Food and Drug Administration (FDA) has approved Siam Bioscience as a manufacturing facility for AstraZeneca’s Covid-19 vaccine. The company, together with Siam Bioscience, has been working tirelessly to ensure that the facility is on track to safely deliver supply to support the national vaccination campaign. The collaboration with the Thai government and the FDA has facilitated the swift but careful progress with the manufacturing plant over the past few months, according to a statement issued by AstraZeneca (Thailand) Ltd on Wednesday.
James Teague, Country President, AstraZeneca (Thailand) Ltd, said: “AstraZeneca and our global manufacturing partners, including Siam Bioscience, are committed to maintaining the highest safety and quality standards of our products. Numerous safety tests and quality control measures are carried out at each step. We are working as quickly as possible to supply the vaccine to the Thai government to overcome the ongoing pandemic.”
“Thailand will play a central role to support our neighbours in Southeast Asia to combat Covid-19. Together we can join hands to fight this pandemic,” said Mr Teague.
Read more at Bangkok Post
Photos: NNT, Bangkok Post